Topic: Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Hepatocellular Carcinoma

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common form of liver disease, and its association with hepatocellular carcinoma (HCC) has gained increasing attention. Various demographic, clinical, and genetic variables can impact the risk of HCC in patients with MASLD, potentially providing valuable insights for the development of risk stratification tools. The implementation of periodic surveillance has been found to be linked to enhanced early tumor detection and a decrease in mortality related to HCC. Nevertheless, patients with MASLD face various obstacles when it comes to effective surveillance. The optimal approach to treatment selection is to use a multidisciplinary approach, taking into consideration several criteria such as the tumor extent, the degree of liver impairment, and the patient's performance status. Despite the fact that patients diagnosed with MASLD-related HCC frequently exhibit a greater tumor burden and a higher prevalence of comorbidities, they can attain comparable post-treatment survival rates with meticulous patient selection. The effectiveness of various treatment options for MASLD-related HCC has been a subject of discussion. However, the existing evidence is inadequate to warrant modifications in treatment options according to the underlying cause of liver disease.

This Research Topic will focus on recent advances in the field of MASLD-related HCC. The topics of this collection include, but are not limited to, the following:
1. Epidemiology of MASLD-related HCC;
2. Surveillance and risk stratification for patients with MASLD-related HCC;
3. Diagnostic approaches for MASLD-related HCC;
4. Recent updates in the treatment of MASLD-related HCC, etc.

31 May 2024